Welcome to our dedicated page for GUIDED THERAPEUTICS SEC filings (Ticker: GTHP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GUIDED THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GUIDED THERAPEUTICS's regulatory disclosures and financial reporting.
Guided Therapeutics (GTHP) reported Q3 2025 results. Sales of devices and disposables were $60 thousand with gross profit of $35 thousand, while operating expenses reached $520 thousand. The company posted a net loss of $742 thousand for the quarter and $1.978 million for the nine months.
Liquidity remains tight with cash and cash equivalents of $87 thousand and total assets of $903 thousand against total liabilities of $6.549 million. Stockholders’ deficit was $5.646 million. The company disclosed a going concern uncertainty, citing a working capital deficit of about $5.7 million and ongoing operating losses.
To fund operations year-to-date, GTHP raised $260 thousand via private placements and $623 thousand in notes (including related parties), and issued 18.47 million shares from conversions, financing, and interest/dividends paid in stock. Deferred revenue stood at $689 thousand, short-term convertible debt in default was $1.130 million, and 83,599,156 common shares were outstanding as of November 10, 2025.